There is a distinct need in the marketplace for non-antibiotic therapeutics to alleviate stubborn GI infections and for treatments that mitigate inflammatory disease in the gastrointestinal system. Orally administered antibodies are particularly attractive as they can be easily ingested, for example in medical or functional food formats.
Please contact us for more information on orally-administered antibodies.
Clostridium difficile (C. diff)
C. diff is a pathogenic bacterium that mainly affects older adults and immunocompromised patients in healthcare facilities. It causes gastrointestinal symptoms ranging from diarrhea to life-threatening inflammation of the colon. Over the years, in part due to antibiotic resistance, C. diff infections have become increasingly severe and more challenging to treat.
We are currently developing orally-administered antibodies to help prevent and treat C. diff infections. Using rationalized design, we have identified optimal antigens for C. diff attenuation and used these to immunize chickens. High-potential candidates have been selected from antibody panels derived from immunized chickens’ lymphoid glands. These have been pooled into candidate “cocktails” containing antibodies against the bacterial cell surface as well as C. diff toxins and spores. The candidate cocktails have already undergone some pre-clinical testing: they have been shown to reduce adherence of C. diff bacteria to cells in the GI tract, to neutralize C. diff toxins, and also to decrease mucosal damage in a mouse model.
Purinergic receptor P2Y6
P2Y6 has been implicated in bacterial infection of the GI tract. Immune Biosolutions is currently evaluating polyclonal and recombinant antibodies produced by the Nebula Antibody Platform for applications in colorectal cancer as well as GI infection and inflammation.